Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.87 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.87 |
| ▸ | PPARG | P37231 | 7/20 | 0.87 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.87 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | PTGES | O14684 | 1/20 | 0.79 |
| ▸ | XPO1 | O14980 | 1/20 | 0.79 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | RARB | P10826 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8951520 | 0.93 | CYSLTR1 (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| SCHEMBL4456175 | 0.93 | CYSLTR1 (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| SCHEMBL4164081 | 0.92 | CYSLTR1 (0.88) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| SCHEMBL8951510 | 0.92 | CYSLTR1 (0.99) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL4175 | 0.88 | PLA2G4A (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL6600322 | 0.88 | PLA2G4A (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL29861631 | 0.88 | PLA2G4A (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL30885065 | 0.88 | PLA2G4A (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL29372773 | 0.88 | PLA2G4A (1.00) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A | |
| Zafirlukast SCHEMBL4586973 | 0.88 | PLA2G4A (0.99) | CYSLTR1EPHX2PPARGCYSLTR2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149662-A1 | PROCESSES FOR PREPARING ZAFIRLUKAST | SI, FIP1L1, KHK | CYSLTR1 881/4885EPHX2 3820/4885PPARG 1579/4885 |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | PRSS3, PRSS1, PRSS2 | CYSLTR1 1940/4885EPHX2 3791/4885PPARG 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.